 |
 |
 |
 |
 |
 |
 |
|
|||||||
|
 |
|||
 |
|||
|
|||
|
||||||||
| Click here to download the entire interview | ||||||||
| Track 1 | Introduction |  |
||||||
| Track 2 | Adjuvant chemotherapy for Stage II colon cancer | |
||||||
| Track 3 | Development and validation of a prognostic assay in colon cancer | |
||||||
| Track 4 | Perspectives on ECOG-E5202 adjuvant trial design | |
||||||
| Track 5 | NSABP-C-08: FOLFOX with or without bevacizumab in the adjuvant setting | |
||||||
| Track 6 | Future adjuvant NSABP colon trial design | |
||||||
| Track 7 | Emerging clinical research on panitumumab | |
||||||
| Track 8 | NSABP-C-09: CAPOX with or without hepatic arterial infusion of FUDR following hepatic resection | |
||||||
| Track 9 | NSABP-C-10: FOLFOX plus bevacizumab for patients with a synchronous primary lesion and metastatic disease | |
||||||
| Track 10 | Perspectives on NSABP-R-04 trial design | |
||||||
| Track 11 | Adjuvant chemotherapy for rectal cancer | |
||||||
|
||||||||
| Click here to download the entire interview | ||||||||
| Track 1 | Introduction | |
||||||
| Track 2 | EGFR inhibitors in the management of colon cancer | |
||||||
| Track 3 | Clinical trial experience with cetuximab | |
||||||
| Track 4 | Synergy between cetuximab and chemotherapy | |
||||||
| Track 5 | Similarities and differences between panitumumab and cetuximab | |
||||||
| Track 6 | Incorporating EGFR inhibitors into the treatment algorithm | |
||||||
| Track 7 | Management of rash associated with EGFR inhibitors | |
||||||
| Track 8 | Potential role of panitumumab in clinical practice | |
||||||
| Track 9 | Adjuvant chemotherapy for Stage II colon cancer | |
||||||
| Track 10 | Adjuvant capecitabine for patients with Stage II disease | |
||||||
| Track 11 | Case discussion: An 84-year-old man with Stage II colon cancer | |
||||||
|
||||||||
| Click here to download the entire interview | ||||||||
| Track 1 | Introduction | |
||||||
| Track 2 | Background, design and results of TREE-1 and TREE-2 trials | |
||||||
| Track 3 | Efficacy of bFOL regimen in TREE-1 and TREE-2 | |
||||||
| Track 4 | Selection of first-line therapy for metastatic disease | |
||||||
| Track 5 | Management of patients with neurotoxicity who progress on FOLFOX with bevacizumab | |
||||||
| Track 6 | Management of oxaliplatin-associated neurotoxicity | |
||||||
| Track 7 | Selection of first-line therapy for patients who have received adjuvant FOLFOX | |
||||||
| Track 8 | Potential benefits of panitumumab versus cetuximab | |
||||||
| Track 9 | Future directions in the management of colon cancer | |
||||||
|
||||||||
| Click here to download the entire interview | ||||||||
| Track 1 | Introduction | |
||||||
| Track 2 | Side-effect profile of bevacizumab | |
||||||
| Track 3 | Bowel perforation associated with bevacizumab | |
||||||
| Track 4 | Bevacizumab-related hypertension | |
||||||
| Track 5 | Predictive risk factors for arterial thromboembolic events with bevacizumab | |
||||||
| Track 6 | Potential rationale for lack of benefit with adjuvant irinotecan | |
||||||
| Track 7 | Impact of exercise and diet on cancer relapse | |
||||||
| Track 8 | Selection of adjuvant chemotherapy | |
||||||
| Track 9 | Role of capecitabine in the adjuvant setting | |
||||||
| Track 10 | Substitution of capecitabine for 5-FU as neoadjuvant therapy for rectal cancer | |
||||||
| Track 11 | First-line therapy for metastatic disease | |
||||||
| Track 12 | Sequencing panitumumab in the clinical algorithm | |
||||||
| Track 13 | Potential benefits and challenges of combined biologic therapy | |
||||||
|
||||||
| Click here to download the entire segment | ||||||
| Track 1 | Introduction | |
||||
| Track 2 | Differences between management of breast and colon cancer | |
||||
| Track 3 | Historical perspective on the role of adjuvant chemotherapy for Stage II colon cancer | |
||||
| Track 4 | Ongoing development of prognostic assays to predict benefit of adjuvant chemotherapy in colon cancer | |
||||
| Track 5 | Patient perspectives on adjuvant chemotherapy for Stage II disease | |
||||
| Track 6 | Differences in medical oncologists’ approach to colon cancer | |
||||
| Track 7 | Safety and efficacy of bevacizumab | |
||||
| Track 8 | Hypertension as a predictor of response to bevacizumab | |
||||
| Track 9 | Utility of EGFR staining in clinical decision-making | |
||||
| Track 10 | Efficacy and tolerability of cetuximab | |
||||
| Track 11 | Phase III trial of best supportive care with or without panitumumab | |
||||
| Track 12 | Impact of rash on use of EGFR inhibitors | |
||||
| Track 13 | Potential role of combined biologic therapy | |
||||
| Track 14 | Future directions for NSABP adjuvant colon cancer trials | |
||||
| Track 15 | Selection of panitumumab versus cetuximab in clinical practice | |
||||
| Track 16 | TREE-1 and TREE-2 trials evaluating oxaliplatin/fluoropyrimidine regimens with and without bevacizumab as first-line therapy | |
||||
